Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
UNIGUIDE-1: Phase 3 UBT251 versus placebo in type 2 diabetes inadequately controlled with diet and exercise
ChiCTR2600134319Phase 3Not yet recruiting
- Sponsor
- The Second Xiangya Hospital
- Start
- Aug 2026
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of UBT251 in type 2 diabetes mellitus (T2DM) (4 arms), sponsored by The Second Xiangya Hospital. Primary endpoint: Change from baseline in HbA1c at Week 40. Planned start Aug 2026; status: not yet recruiting.
02
Drugs
UBT251
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on ChiCTR2600134319.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600134319.